Global Ion Channel Modulators Industry

News provided by

Jul 29, 2013, 07:30 ET

NEW YORK, July 29, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Ion Channel Modulators Industry

http://www.reportlinker.com/p01171462/Global-Ion-Channel-Modulators-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

This report analyzes the worldwide markets for Ion Channel Modulators in US$ Million.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 48 companies including many key and niche players such as AstraZeneca, Aurora Biomed, Inc., CalciMedica, Inc., Cellectricon AB, Convergence Pharmaceuticals Limited, Cytocentrics AG, Evotec AG, flyion GmbH, GlaxoSmithKline Plc, Neusentis, Inc., Nanion Technologies GmbH, NeuroSearch A/S, Novartis AG, Parion Sciences, Inc., Pfizer, Inc., Sanofi, Targacept, Inc., Xention Limited, and Zalicus, Inc. Microsoft Corporation, QNX Software Systems Ltd., Renesas Electronics Corporation, VIA Technologies, Inc., and Zilog, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Prelude II-1

Market Overview II-1

Current Ion Channel Modulating Drugs in the Market II-2

Select Ion Channel Drugs in the Global Market By Disease

Indication II-2

Ion Channel Modulators under Development- A Few Key Facts II-2

Select Ion Channel Modulators under Development by Disease

Indication II-3

Current & Future Analysis II-3

Growth Factors-A Glance II-3

Trends II-3

Technological Advancements in Ion Channel Screening Driving

Drug Development II-3

Increased Interest Witnessed in Outsourcing of Ion Channel

Services II-4

Expanding Areas of Application II-4

Ion Channel Modulators Find Extensive Usage for Treating

Neglected Tropical Diseases II-4

Ion Channel Modulation in Pain Management II-5

Ion Channel Modulation in Oncology II-5

Limitations and Challenges II-5

Ion Channels - Difficult Drug Targets II-5

The threat posed by the influx of generic drugs II-6

Competitive Scenario II-6

2. PRODUCT OVERVIEW II-7Ion Channel Modulators: An Introduction II-7Biological Significance of Ion Channels II-7Ion Channel Modulators as an Option for Treating Diseases II-7Types of Ion Channels II-8Voltage-Gated Ion Channels II-8Extracellular Ligand-gated Ion Channels II-9Intracellular Ligand-gated Ion Channels II-11

3. PRODUCT LAUNCHES/INTRODUCTIONS II-13

Vertex Pharmaceuticals Receives USFDA Approval for KALYDECO™ II-13

Glenmark Pharmaceuticals Discovers Novel Chemical Entity (NCE)

'GRC 17536' Program II-13

BioFocus DPI Rolls Out Novel Biologically- Targeted Libraries II-14

4. RECENT INDUSTRY ACTIVITY II-15Aurora Biomed Inks Agreement with Specs and Alion Pharmaceuticals II-15Hydra and Zalicus Enter into Partnership II-15Hydra Biosciences and Cubist Pharmaceuticals to Commence Phase1 Clinical Trial for TRPA1 Antagonist CB-625 II-15UCB Takes Over Key Pharmaceutical Assets of Lectus Therapeutics II-16Xention Collaborates with Grünenthal II-16US FDA Lifts Clinical Hold on ICA-105665 of Icagen II-16Ono Pharmaceutical Collaborates with BioFocus DPI II-17Zalicus to Advance Development of Drug Candidate II-17APEPTICO Concludes Phase I Clinical Trial of AP301 II-17NeuroSearch Restructures Itself to Focus on CNS Drug Development II-18Evotec Inks License and Collaboration Agreement for EVT401 II-19Evotec and Ono Pharmaceutical Extend Research Collaboration II-19Evotec Acquires DeveloGen II-19Essen Instruments Enters into Alliance with OriGene Technologies II-20Glenmark Pharmaceuticals Inks License Agreement with Sanofi-aventis II-20Evotec and Active Biotech Enter into Collaboration II-20CombinatoRx Changes Name to Zalicus II-21Cytocentrics Expands Ion Channel CRO Screening Services II-21Icagen and Applied Genetic Technologies Ink Sale and PurchaseAgreement II-21Evotec Collaborates with Almirall for Identification of IonChannel Target Modulators II-22Essen BioScience and Nycomed Sign Joint Discovery Agreement II-22Axxam and Polyphor Ink Joint Discovery Agreement II-22ChanTest Takes Over Applied Cell Sciences II-23CombinatoRx Merges with Neuromed Pharmaceuticals II-23Axxam Signs Research Collaboration Agreement with Xenome II-24Xention and Ono Pharmaceutical Ink Drug Discovery Agreement II-24NeuroSearch Enters Into Collaboration Alliance with Eli Lilly II-24Synta Pharmaceuticals Enters Into Strategic Alliance withRoche Holding II-24AstraZeneca Inks License and Collaboration Agreement withTargacept II-25Abbott Inks Definitive Agreement to Take Over Rights of PG110Fully Humanized Antibody of PanGenetics II-25Evotec and Alios BioPharma Enter into Collaboration II-26Cellectricon and BioFocus DPI Enter into Collaboration II-26Pfizer Inks License and Collaboration Agreement with Icagen II-26Dompé farmaceutici Renews Research Collaboration with Axxam II-27Can-Fite BioPharma Completes Licensing Agreement with LeidenUniversity and NIH for Allosteric Modulators II-27

5. FOCUS ON SELECT GLOBAL PLAYERS II-28

AstraZeneca (UK) II-28

Aurora Biomed, Inc. (Canada) II-28

CalciMedica, Inc. (US) II-28

Cellectricon AB (Sweden) II-29

Convergence Pharmaceuticals Limited (UK) II-29

Cytocentrics AG (Germany) II-30

Evotec AG (Germany) II-30

flyion GmbH (Germany) II-30

GlaxoSmithKline Plc. (UK) II-31

Neusentis, Inc. (US) II-31

Nanion Technologies GmbH (Germany) II-32

NeuroSearch A/S (Denmark) II-32

Novartis AG (Switzerland) II-32

Parion Sciences, Inc. (US) II-33

Pfizer, Inc. (US) II-33

Sanofi (France) II-34

Targacept, Inc. (US) II-34

Xention Limited (UK) II-34

Zalicus, Inc. (US) II-35

6. GLOBAL MARKET PERSPECTIVE II-36Table 1: World Recent Past, Current and Future Analysis forIon Channel Modulators by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), Latin America,and Rest of World Markets Independently Analyzed with AnnualSales in US$ Million for Years 2010 through 2018 (includescorresponding Graph/Chart) II-36

Table 2: World Historic Review for Ion Channel Modulators by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America, and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2004 through 2009 (includes corresponding Graph/Chart) II-37

Table 3: World 15-Year Perspective for Ion Channel Modulatorsby Geographic Region - Percentage Breakdown of Dollar Salesfor US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),Latin America, and Rest of World Markets for Years 2004, 2012,and 2018 (includes corresponding Graph/Chart) II-38III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Overview III-1

Strategic Corporate Developments III-1

Key Players III-6

B.Market Analytics III-9

Table 4: The US Recent Past, Current and Future Analysis for

Ion Channel Modulators with Annual Sales in US$ Million for

Years 2010 through 2018 (includes corresponding Graph/Chart) III-9

Table 5: The US Historic Review for Ion Channel Modulatorswith Annual Sales in US$ Million for Years 2004 through 2009(includes corresponding Graph/Chart) III-10

2. CANADA III-11

A.Market Analysis III-11

Strategic Corporate Development III-11

Aurora Biomed, Inc. - A Key Player III-11

B.Market Analytics III-12

Table 6: Canadian Recent Past, Current and Future Analysis

for Ion Channel Modulators with Annual Sales in US$ Million

for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-12

Table 7: Canadian Historic Review for Ion Channel Modulatorswith Annual Sales in US$ Million for Years 2004 through 2009(includes corresponding Graph/Chart) III-13

3. JAPAN III-14

A.Market Analysis III-14

Strategic Corporate Developments III-14

B.Market Analytics III-15

Table 8: Japanese Recent Past, Current and Future Analysis

for Ion Channel Modulators with Annual Sales in US$ Million

for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-15

Table 9: Japanese Historic Review for Ion Channel Modulatorswith Annual Sales in US$ Million for Years 2004 through 2009(includes corresponding Graph/Chart) III-16

4. EUROPE III-17

A.Market Analysis III-17

Overview III-17

B.Market Analytics III-18

Table 10: European Recent Past, Current and Future Analysis

for Ion Channel Modulators by Country/Region - France,

Germany, Italy, UK, Spain, and Rest of Europe Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2010 through 2018 (includes corresponding Graph/Chart) III-18

Table 11: European Historic Review for Ion ChannelModulators by Country/Region - France, Germany, Italy, UK,Spain, and Rest of Europe Markets Independently Analyzedwith Annual Sales in US$ Million for Years 2004 through 2009(includes corresponding Graph/Chart) III-19

Table 12: European 15-Year Perspective for Ion Channel

Modulators by Country/Region - Percentage Breakdown of

Dollar Sales for France, Germany, Italy, UK, Spain, and Rest

of Europe Markets for Years 2004, 2012, and 2018 (includes

corresponding Graph/Chart) III-20

4a. FRANCE III-21A.Market Analysis III-21Sanofi - A Key Player III-21B.Market Analytics III-22Table 13: French Recent Past, Current and Future Analysisfor Ion Channel Modulators with Annual Sales in US$ Millionfor Years 2010 through 2018 (includes correspondingGraph/Chart) III-22

Table 14: French Historic Review for Ion Channel Modulators